Advertisement

Morbus Parkinson und Sexualität

  • A. Hendrich
Conference paper
  • 67 Downloads

Zusammenfassung

Die Parkinsonkrantkheit geh00F6;rt zu den h00E4;figen neurodegenerativen Erkrankungen. Die Pravalenz der Erkr00E4;nkung wird f00FC;r Mittel- und Nordeuropa mit ca. 160 pro 100.000 angegeben. Die Erkrankungshaufigkeit nimmt mit dem Alter zu. Die Pravalenz bei den 00FC;ber 60-j00E4;hrigen liegt bei ca. 1% bei den 00FC;ber 80-jahrigen gegen 3%. M00E4;nner und Frauen sind etwa gleich h00E4;ufig betroffen. Das Erkrankungsalter liegt in 10% der Falle vor dem 40. Lebensjahr, 40% der Patienten erkranken zwischen dem 50. und 60. Lebensjahr. Man geht davon aus, dass in Deutschland ca. 250.000 Menschen an der Parkinsonkrankheit leiden [8,30].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Anderson KE (2001) Pharmacology of penile erection. Pharmacological reviews. 53: 417–450Google Scholar
  2. 2.
    Beier KM (2000) Sexualitat und Partnerschaft. Leitfaden fur Betroffene und ihre Partner. Pairdata GmbH, Potsdam-Babelsberg, S 7–56Google Scholar
  3. 3.
    Brock B, Bochinski D (2001) Modern pharmacotherapy for erectile dysfunction: evolving concepts with central and peripheral acting agents. Current Opinion in Urology 11: 625–630PubMedCrossRefGoogle Scholar
  4. 4.
    Brockhaus (2000) Bibliographisches Institut, MannheimGoogle Scholar
  5. 5.
    Brown RG, Jahanshahi M, Quinn N, Marsden CD (1990) Sexual function in patients with Parkinson’s disease and their partners. J Neurol Neurosurg Psychiatry 53: 480–486CrossRefGoogle Scholar
  6. 6.
    Feldmann HA, Goldstein I, Hatzichristou DG et al. (1994) Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 151: 54–61Google Scholar
  7. 7.
    Freud S (1990) Trieblehre. In: Freud S (Hrsg) Abriss der Psychoanalyse. Fischer, Frankfurt am Main, S 44–47Google Scholar
  8. 8.
    Gerlach M, Reichmann H, Riederer P (2001) Die Parkinsonkrankheit, Grundlagen, Klinik, Therapie. Springer, Wien, S 24–81Google Scholar
  9. 9.
    Graf KJ, Kiirten I (1983) Effects of dopamine agonists on prolactin, growth hormone, and cortisol secretion in animals and humans. In: Caine D, Horowski R, McDonald R, Wuttke W (eds) Lisuride and Other Dopamine Agonists. Raven Press, New York, pp 199–229Google Scholar
  10. 10.
    Guiliano F, Allard J (2001) Dopamine and male sexual function. European Urology 40: 601–608CrossRefGoogle Scholar
  11. 11.
    Guiliano F, Allard J (2002) Apomorphine SA: Preclinical and clinical experiences learned form the first central nervous system-acting ED drug. Int J Impot Res 14: 53–56CrossRefGoogle Scholar
  12. 12.
    Heaton JP (2000) Central neuropharmacological agents and mechanisms in erectile dysfunction: The role of dopamine. Neurosci Biobehav Res 24: 561–569CrossRefGoogle Scholar
  13. 13.
    Heinz A (1999) Anhedonienosologieiibergreifendes Korrelat einer Dysfunktion des dopaminergen Verstarkungssystems. Nervenarzt 5: 391–397CrossRefGoogle Scholar
  14. 14.
    Hilz, MJ, Hecht M, Kolsch C (2000) Erektile Dysfunktion. Aktuelle Neurologie 27: 1–12CrossRefGoogle Scholar
  15. 15.
    Horowski R (1983) Pharmacological effects of lisuride and their potential role in further research. In: Caine D, Horowski R, McDonald R, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 127–139Google Scholar
  16. 16.
    Jost WH, Braune S (2001) Autonome Regulationsstorungen beim idiopathischen Parkinsonsyndrom. Aktuelle Neurologie 28, S 3: 235–241Google Scholar
  17. 17.
    Keller HH, Bonetti EP, Pieri L, Da Prada M (1983) Lisuride-induced mounting behavior and effects on the monoaminergic system in rat brain. In: Caine D, Horowski R, McDonald R, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 79–87Google Scholar
  18. 18.
    Koller WC, Vetere-Overfield B, Williamson A, Busenbark K, Nash J, Parrish D (1990) Sexual dysfunction in Parkinson’s disease. Clin Neuropharmacol 5: 461–463CrossRefGoogle Scholar
  19. 19.
    Koulousakis A, Nittner K (1984) Parkinson’sche Erkrankung und Sexualfunktion. Vegetativstorungen beim Parkinsonsyndrom. In: 4. Frankfurter Parkinson-Symposium. Editiones Roche, Basel, S 189–208Google Scholar
  20. 20.
    Lambert D, Waters CH (1998) Sexual dysfunction in Parkinson’s disease. Clin Neurosci 5: 73–77PubMedCrossRefGoogle Scholar
  21. 21.
    Lipe H, Longstreth WT Jr, Bird TD, Linde M (1990) Sexual function in married men with Parkinson’s disease compared to married men with arthritis. Neurology 40: 1347–1349PubMedCrossRefGoogle Scholar
  22. 22.
    Marsden C (1990) Parkinson’s disease. Lancet 335: 948–952PubMedCrossRefGoogle Scholar
  23. 23.
    Martignoni E, Pacchetti C, Micieli G, Nappi G (1995) Autonomic disturbances in Parkinson’s disease and Shy-Drager-Syndrome. In: Korczyn AD (ed) Handbook of Autonomic Nervous System Dysfunction. Dekker, New York, pp 237–252Google Scholar
  24. 24.
    Nehra A, Moreland RB (2001) Neurologic erectile dysfunction. Urol Clin North Am 28: 289–308PubMedCrossRefGoogle Scholar
  25. 25.
    NIH consensus development panel on impotence (1993) 111.Impotence. JAMA 270: 83–90Google Scholar
  26. 26.
    Nusselt L, Stief CG (1997) Neuroanatomie der Sexualfunktion und Pathophysiologie der Sexualstorung. In: Stiihrer M, Madersbacher H, Palmtag H (Hrsg) Neurogene Blasenfunktionsstorung. Neurogene Sexualstorung. Springer, Berlin Heidelberg, S 267–274CrossRefGoogle Scholar
  27. 27.
    Okun MS, McDonald WM, DeLong MR (2002) Refractory nonmotor systems in male patients with Parkinson’s disease due to testosterone deficiency: a common unrecognized comorbidity. Arch Neurol 59: 807–811PubMedCrossRefGoogle Scholar
  28. 28.
    Okun MS, Walter BJ, McDonald WM et al. (2002) Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson’s disease. Arch Neurol 59: 1750–1753PubMedCrossRefGoogle Scholar
  29. 29.
    Peters HJ (1991) Neuroanatomie und Neurophysiologie des unteren Harntraktes. In: Madersbacher H, Palmtag H (Hrsg) Detrusorrelaxation. Grundlagen und klinische Aspekte. PVV-Verlag Preuss, Ratingen, S 16–27Google Scholar
  30. 30.
    Poewe W, Ceballos-Baumann 0, Conrad B (1996) Parkinsonkrankheit. In: Conrad B, Ceballos-Baumann 0 (Hrsg) Bewegungsstorungen in der Neurologie. Thieme, Stuttgart, S 30–67Google Scholar
  31. 31.
    Pomeranz SM (1992) Dopaminergic influences on male sexual behavoir of rhesus monkeys: Effecs of dopamine agonists. Pharmacol Biochem Behav 41: 511–517CrossRefGoogle Scholar
  32. 32.
    Raffaele R, Vecchio I, Giammusso B et al. (2002) Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson’s disease. Eur Urol 41: 382–386PubMedCrossRefGoogle Scholar
  33. 33.
    Riederer P (1984) Das vegetative Nervensystem bei der Parkinsonkrankheit: Neurochemische Aspekte. Vegetativstorungen beim Parkinsonsyndrom. In: 4. Frankfurter Parkinson Symposium. Editiones Roche, Basel, S 63–73Google Scholar
  34. 34.
    Ruilope L, Garcia-Robles R, Paya C et al. (1983) Influence of Lisuride, a dopaminergic agonist, on the sexual function of male patients with chronic renal failure. Am J Kidney Dis 3: 182–185Google Scholar
  35. 35.
    Sakakibara R, Shinotoh H, Uchiyma T et al. (2001) Questonnaire-based assesment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci 92: 76–85PubMedCrossRefGoogle Scholar
  36. 36.
    Shabisgh R (2000) Recent developments in male sexual dysfunction. Curr Psychiatry Rep 2: 196–200CrossRefGoogle Scholar
  37. 37.
    Singer C (1995) Sexual dysfunction. In: Korczyn AD (ed) Handbook of autonomic nervous system dysfunction. Dekker, New York, pp 381–397Google Scholar
  38. 38.
    Singer C, Sanchez-Ramos J, Weiner WJ, Ackerman M (1989) Sexual dysfunction in parkinsonian males. Neurology: 145Google Scholar
  39. 39.
    Singer C, Weiner WJ, Sanchez-Ramos JR (1992) Autonomic dysfunction in men with Parkinson’s disease. Eur Neurol 32: 134–140PubMedCrossRefGoogle Scholar
  40. 40.
    Weig W (2000) Die Rolle von Psychiatric und Psychotherapie in der Sexualmedizin nach der Markteinfiihrung von Viagra. Nervenarzt 3: 218–221CrossRefGoogle Scholar
  41. 41.
    Wein AJ, Walsh PC et al. (1998) Neuromuscular dysfunction of the lower urinary tract and its treatment. Campell’s Urology, 7th edn. WB Saunders, Philadelphia, pp 953–1006Google Scholar
  42. 42.
    Zahran AR, Simmermann N, Carrier S, Vachon P (2001) Erectile dysfunction occurs following substantia nigra lessons in the rat. Int J Impot Res 13: 255–260PubMedCrossRefGoogle Scholar
  43. 43.
    Zesiewicz TA, Helal M, Hauser RA (2000) Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson’s disease. Mov Disord 15: 305–308PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • A. Hendrich

There are no affiliations available

Personalised recommendations